Minimally Invasive Biomarker for Asthma Disease Severity
NCT ID: NCT02225678
Last Updated: 2016-05-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
25 participants
OBSERVATIONAL
2014-07-31
2015-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarkers in Exhaled Breath From Asthmatic Patients
NCT00635271
Characteristics of Type 2- High Inflammatory Endotype of Asthma Using New Biomarkers From Peripheral Blood and Exhaled Air and Its Effect on the Outcome of Therapy
NCT05270278
Asthma Biomarker Study
NCT02392481
Changes in Gene Transcription and Immunophenotypes Following Mepolizumab Treatment for Asthma
NCT05002621
Phenotyping Disease Severity in Asthma
NCT05078021
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Develop a point-of-service assay to assess eosinophilic airway inflammation
Proposal Specific Aims:
1. To establish the infrastructure and test the feasibility of sputum collection in a clinical setting as a minimally invasive patient sampling process for biomarker testing
2. To transform the laboratory-based eosinophil peroxidase (EPX) ELISA detection assay into a clinic-friendly assessment that does not require sophisticated laboratory equipment
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* FeNO\>50 ppb
* FEV1 \> 1.0 Liter
Exclusion
* COPD by history
* Bronchiectasis by history
* Pregnant participants
Normal subjects:
Inclusion
\- Age matched to asthma subjects
Exclusion
* Any eosinophil disorder by history
* Asthma by history
* Rhinitis or sinusitis by history
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
James J. Lee, Ph.D.
PI
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
James Lee, PhD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic in Arizona
Scottsdale, Arizona, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14-001168
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.